Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia A multicenter, randomized trial of tailored counseling versus standard information

被引:26
|
作者
Ingrand, Isabelle [1 ,2 ,3 ]
Defossez, Gautier [1 ,2 ,3 ]
Richer, Jean-Pierre [4 ]
Tougeron, David [5 ]
Palierne, Nicolas [6 ]
Letard, Jean-Christophe [7 ]
Beauchant, Michel [6 ]
Ingrand, Pierre [1 ,2 ,3 ]
机构
[1] INSERM, CIC 1402, Poitiers, France
[2] Univ Poitiers, Unite Epidemiol & Biostat, Registre Canc Poitou Charentes, Poitiers, France
[3] Ctr Hosp Univ Poitiers, Pole Sante Publ, Poitiers, France
[4] Ctr Hosp Univ Poitiers, Serv Chirurg Digest, Poitiers, France
[5] Ctr Hosp Univ Poitiers, Serv Hepatogastroenterol, Poitiers, France
[6] Polyclin Poitiers, GRESCO, Poitiers, France
[7] Polyclin Poitiers, CREGG, Club Reflex Cabinets & Grp Gastroenterologues, Poitiers, France
关键词
colonoscopy; colorectal cancer; first-degree relative; screening; tailored intervention; SOCIETY-TASK-FORCE; SCREENING PARTICIPATION; CANCER PATIENTS; INTERVENTIONS; SURVEILLANCE; TELEPHONE; RELATIVES; ADENOMAS; SIBLINGS; MEMBERS;
D O I
10.1097/MD.0000000000004303
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Colonoscopic screening is recommended for first-degree relatives of patients diagnosed with colorectal cancer (CRC) or colorectal adenomatous polyps (CAP) before the age of 60 years. This has the potential to reduce CRC-related morbidity and mortality, but uptake is currently inadequate. Methods: The aim of the study was to compare the effectiveness of standard information versus a nurse-led tailored intervention designed to promote uptake of colonoscopy screening by siblings of CRC or CAP patients. A randomized controlled trial was conducted. Digestive surgeons and gastroenterologists recruited index patients who developed CRC or CAP before the age of 60 years. All index patients received standard screening information for their siblings, in keeping with current guidelines. Centrally computerized randomization of index patients resulted in allocating all their siblings to the same group, intervention or control. The tailored intervention targeted the index patient first, to help them convey information to their siblings. The nurse then provided the siblings with tailored information based on their answers to a self-questionnaire which explored health behaviors, derived from psychosocial models of prevention. Then the siblings were given a personalized information leaflet to hand to their regular physician. The primary endpoint was the rate of documented colonoscopy performed in siblings within 1 year after diagnosis of the index patient. The intent-to-treat analysis included siblings who refused to participate in the study. Statistical analysis was adjusted for intrafamilial correlation. Results: A total of 304 siblings of 125 index patients were included: 160 in the intervention group and 144 in the control group. The rate of colonoscopy uptake among siblings was 56.3% in the intervention group and 35.4% in the control group (P=0.0027). The respective rates after exclusion of refusals were 69.2% and 37.0% (P<0.0001). More lesions were detected in the intervention group (1 invasive cancer and 11 advanced adenomas vs 5 advanced adenomas; P=0.022). Conclusions: This study demonstrates the effectiveness of a nurse-led tailored intervention designed to promote colonoscopy screening uptake by siblings of patients diagnosed with CRC or CAP before age 60 years. Such tailored interventions that also involve physicians should help to reduce CRC-related mortality.
引用
收藏
页数:7
相关论文
共 8 条
  • [1] Motivational interviewing and screening colonoscopy in high-risk individuals. A randomized controlled trial
    Salimzadeh, Hamideh
    Khabiri, Roghaye
    Khazaee-pool, Maryam
    Salimzadeh, Somayeh
    Delavari, Alireza
    PATIENT EDUCATION AND COUNSELING, 2018, 101 (06) : 1082 - 1087
  • [2] A Randomized Trial to Increase Colonoscopy Screening in Members of High-Risk Families in the Colorectal Cancer Family Registry and Cancer Genetics Network
    Lowery, Jan T.
    Horick, Nora
    Kinney, Anita Y.
    Finkelstein, Dianne M.
    Garrett, Kathleen
    Haile, Robert W.
    Lindor, Noralane M.
    Newcomb, Polly A.
    Sandler, Robert S.
    Burke, Carol
    Hill, Deirdre A.
    Ahnen, Dennis J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (04) : 601 - 610
  • [3] Intervention Mediators in a Randomized Controlled Trial to Increase Colonoscopy Uptake Among Individuals at Increased Risk of Familial Colorectal Cancer
    Brumbach, Barbara H.
    Birmingham, Wendy C.
    Boonyasiriwat, Watcharaporn
    Walters, Scott
    Kinney, Anita Y.
    ANNALS OF BEHAVIORAL MEDICINE, 2017, 51 (05) : 694 - 706
  • [4] Impact of Risk Assessment and Tailored versus Nontailored Risk Information on Colorectal Cancer Testing in Primary Care: A Randomized Controlled Trial
    Skinner, Celette Sugg
    Halm, Ethan A.
    Bishop, Wendy Pechero
    Ahn, Chul
    Gupta, Samir
    Farrell, David
    Morrow, Jay
    Julka, Manjula
    McCallister, Katharine
    Sanders, Joanne M.
    Marks, Emily
    Rawl, Susan M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (10) : 1523 - 1530
  • [5] A Stool DNA-Based SDC2 Methylation Test for the Early Detection of Colorectal Cancer in an Asymptomatic, High-Risk Population: A Multicenter Prospective Randomized Trial
    Kim, Chang Woo
    Kim, Hyunjin
    Kim, Hyoung Rae
    Won, Daeyeon David
    Nam, Woo Jung
    Min, Byung Soh
    Oh, Tae Jeong
    An, Sungwhan
    Lee, Suk-Hwan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (03) : 614 - 622
  • [6] Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial)
    Chihiro Kosugi
    Keiji Koda
    Nobuhiro Takiguchi
    Satoru Takaishi
    Hideaki Miyauchi
    Nobuo Hirayama
    Yukihiro Nomura
    Eisuke Kondo
    Yohei Kawasaki
    Yoshihito Ozawa
    Hisahiro Matsubara
    International Journal of Colorectal Disease, 2021, 36 : 1739 - 1749
  • [7] Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial)
    Kosugi, Chihiro
    Koda, Keiji
    Takiguchi, Nobuhiro
    Takaishi, Satoru
    Miyauchi, Hideaki
    Hirayama, Nobuo
    Nomura, Yukihiro
    Kondo, Eisuke
    Kawasaki, Yohei
    Ozawa, Yoshihito
    Matsubara, Hisahiro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (08) : 1739 - 1749
  • [8] S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial
    Sunami, Eiji
    Kusumoto, Tetsuya
    Ota, Mitsuyoshi
    Sakamoto, Yoshiyuki
    Yoshida, Kazuhiro
    Tomita, Naohiro
    Maeda, Atsuyuki
    Teshima, Jin
    Okabe, Michio
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Takenaka, Naruhito
    Okude, Ryota
    Sugihara, Kenichi
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 22 - +